Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9HCR9

UPID:
PDE11_HUMAN

ALTERNATIVE NAMES:
cAMP and cGMP phosphodiesterase 11A

ALTERNATIVE UPACC:
Q9HCR9; Q14CD1; Q53T16; Q96S76; Q9GZY7; Q9HB46; Q9NY45

BACKGROUND:
The protein Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, with its alternative name cAMP and cGMP phosphodiesterase 11A, is integral to cellular signaling. It achieves this by managing the levels of cAMP and cGMP, two critical cyclic nucleotides. This regulation is essential for the proper response of cells to external signals, making it a key player in cellular function.

THERAPEUTIC SIGNIFICANCE:
Linked to Primary pigmented nodular adrenocortical disease 2, which manifests as Cushing syndrome due to bilateral adrenal defects, the protein's study offers insights into novel treatment avenues. The exploration of Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A's function and its genetic variants could pave the way for innovative therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.